Role of YxdJK and DAK in the Enterococcal Envelope Stress Response
Project Number7K08AI135093-05
Former Number5K08AI135093-04
Contact PI/Project LeaderMILLER, WILLIAM R
Awardee OrganizationMETHODIST HOSPITAL RESEARCH INSTITUTE
Description
Abstract Text
Project Summary
This K08 Career Development Award application is intended to support the acquisition of skills and knowledge
needed to fulfill my long-term goal of becoming an independent physician-scientist focused on combating
antimicrobial resistant organisms, a serious threat to medical practice worldwide. Vancomycin resistant
enterococci (VRE) are an example of these pathogens and are a leading cause of healthcare associated
infections affecting critically ill and immunocompromised patients. VRE are categorized by the CDC as a
serious threat requiring the urgent development of novel therapeutic strategies. The lipopeptide antibiotic
daptomycin (DAP) is now a front line agent for VRE infections, but resistance to DAP can arise while on
therapy. The LiaFSR system, a major mediator of the cell envelope stress response, has been strongly
implicated in the development of DAP resistance. Inactivation of this system by deletion of the gene encoding
the LiaR response regulator was shown to re-sensitize enterococci to DAP. However, adaptation of LiaR
deficient strains of both clinical and laboratory origin resulted in DAP resistance, suggesting that alternate
pathways can protect the cell from antibiotic attack. Using whole genome sequencing of adapted strain pairs, I
identified two pathways with novel contributions to DAP and cephalosporin resistance in enterococci, i) the
YxdJK stress response system, and ii) the dihydroxyacetone kinase (DAK) domain protein involved in the
metabolism of extracellular fatty acids. The YxdJK system consists of a sensor histidine kinase (YxdK), a DNA
binding response regulator (YxdJ) and two ATP-binding cassette (ABC) transporters required to confer
resistance to bacitracin. Deletion of the gene encoding the YxdJ response regulator sensitizes Enterococcus
faecalis to both DAP and cephalosporins, despite a functional LiaFSR system. DAP-resistant strains using the
above pathways appear to display a very distinct mechanism of resistance to cell-envelope acting antibiotics.
This proposal is designed to dissect the role of the YxdJK system and the DAK enzyme in two major specific
aims. First, I will characterize the contributions of the YxdJK system to the cell envelope stress response to
antibiotics by defining how the system senses antibiotic stress and what genes are differentially expressed
when the system is active. Second, I will determine the DAK mediated changes that alter membrane
susceptibility to antibiotics, by comparing the membranes of wild type and DAK deletion strains to assess for
changes in phospholipids, envelope structure, membrane protein function, and biofilm formation. The Center
for Antimicrobial Resistance and Microbial Genomics (CARMiG) at the University of Texas Health Science
Center and adjacent institutions of the Texas Medical Center will provide an unparalleled environment to grow
as an investigator, with both an institutional commitment to combating antimicrobial resistance and an intensive
mentorship program dedicated to helping junior faculty make the transition to independence.
Public Health Relevance Statement
Project Narrative
Antibiotic resistance is one of the greatest challenges facing modern medicine, with vancomycin resistant
enterococci posing a serious threat due to resistance to most available antibiotics. This proposal aims to
understand the mechanism by which two novel pathways mediate resistance to daptomycin and
cephalosporins in enterococci. It provides a relevant framework for a young physician-scientist to develop
experience in membrane biology and bioinformatics, and will serve as a platform to identify new targets
needed to combat antibiotic resistance.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
185641052
UEI
XJUCJAYJWYV1
Project Start Date
03-May-2018
Project End Date
30-April-2023
Budget Start Date
01-February-2022
Budget End Date
30-April-2022
Project Funding Information for 2021
Total Funding
$171,151
Direct Costs
$158,473
Indirect Costs
$12,678
Year
Funding IC
FY Total Cost by IC
2021
National Institute of Allergy and Infectious Diseases
$171,151
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7K08AI135093-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7K08AI135093-05
Patents
No Patents information available for 7K08AI135093-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7K08AI135093-05
Clinical Studies
No Clinical Studies information available for 7K08AI135093-05
News and More
Related News Releases
No news release information available for 7K08AI135093-05
History
No Historical information available for 7K08AI135093-05
Similar Projects
No Similar Projects information available for 7K08AI135093-05